Reshma Rangwala - Feb 29, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Signature
/s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala
Stock symbol
KPTI
Transactions as of
Feb 29, 2024
Transactions value $
-$25,493
Form type
4
Date filed
3/4/2024, 07:41 PM
Previous filing
Feb 29, 2024
Next filing
Apr 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Sale -$18.3K -15.7K -4.22% $1.17 356K Feb 29, 2024 Direct F1, F2
transaction KPTI Common Sale -$7.16K -5.97K -1.68% $1.20 350K Mar 1, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.